Johan Fredrik Paulsson

Company: Novo Nordisk

Job title: Director – Incretin & Amylin Biology

Seminars:

Examining the Latest Advancements in GLP-1-Based Therapies: Combining GLP-1 & Amylin Analogues for Obesity & Diabetes Therapy 9:00 am - 9:30 am

Discussing the complementary physiological actions of GLP-1 and amylin in regulating glucose homeostasis, appetite, and satiety Highlighting how the combination of agonists can lead to enhanced glycemic control, weight loss, and improved cardiovascular outcomes compared to monotherapies. Explore potential challenges, such as the development of long-acting dual agonists with sustained efficacy and the need for…Read more

day: Day One